News
News
 |
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 27, 2022- The new collaboration expands upon two successful partnered studies concluded in the recent year
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, announced today the initiation of the third stage of a collaborative...
-
Jan 4, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that presentation of the company's Phase IIa...
-
Dec 21, 2021- Upon closing its IPO the company appointed four new board members. Dr. Ferenc Tracik joined the company's senior management as Chief Scientific Officer.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the expansion of its board of directors with the...
-
Dec 13, 2021
NeuroSense Therapeutics Ltd., (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating...
-
Dec 8, 2021
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as...
-
Oct 19, 2021NeuroSense filed the F-1 Registration Statement with the SEC on October 18th, 2021.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, announced...
-
Sep 29, 2021Mr. Leuchtenberger joins the company as a board member and chairperson, effective October 1, 2021.
NeuroSense Therapeutics, a clinical stage biotechnology company in the field of CNS, is pleased to announce the appointment of Mark Leuchtenberger as its new Chairman of the Board of Directors....
-
Mar 2, 2021The study's primary end-point was obtained successfully, and preliminary clinical signals were observed indicating that PrimeC could be an effective therapeutic for patients with ALS.
NeuroSense Therapeutics, a biotechnology company developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), based on a novel combination drug therapy aiming...
-
Jan 12, 2021NeuroSense, a biotech company developing treatment for ALS, has been granted orphan designation for their first drug, PrimeC, from the European Medicines Agency.
NeuroSense Therapeutics, a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. Their treatment...
-
Nov 18, 2020Following 9-months of treatment with PrimeC, NeuroSense's combination drug, positive trends first seen in the 6-month interim analysis persist, indicating therapeutic potential for ALS patients.
NeuroSense Therapeutics, a biotech company developing PrimeC, a combination drug which aims to slow ALS progression, continues to report promising trends in their NST002 Phase IIa study, conducted...
-
Sep 9, 2020The clinical trial results demonstrate clearly that PrimeC, NeuroSense's combination drug, has significant therapeutic potential for amyotrophic lateral sclerosis (ALS) patients.
NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow ALS progression, announced today that PrimeC was safe and well tolerated in the interim analysis...
-
Feb 6, 2020The clinical trials initiated in the United States and in Israel will evaluate safety, tolerability and efficacy of PrimeC, NeuroSense's product for ALS patients.
NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow or halt ALS progression, announced today the initiation of two clinical studies to evaluate the...
